ITeos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 10, 2022 at 04:13 pm EDT
Share
iTeos Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 41.72 million. Net income was USD 5.63 million compared to net loss of USD 26.46 million a year ago. Basic earnings per share from continuing operations was USD 0.16 compared to basic loss per share from continuing operations of USD 0.75 a year ago. Diluted earnings per share from continuing operations was USD 0.15 compared to diluted loss per share from continuing operations of USD 0.75 a year ago.
For the six months, revenue was USD 194.24 million. Net income was USD 75.21 million compared to net loss of USD 39.99 million a year ago. Basic earnings per share from continuing operations was USD 2.12 compared to basic loss per share from continuing operations of USD 1.14 a year ago. Diluted earnings per share from continuing operations was USD 1.98 compared to diluted loss per share from continuing operations of USD 1.14 a year ago.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
ITEOS THERAPEUTICS, INC. 
